Lecap Asset Management Ltd. Buys Shares of 6,054 Encompass Health Corporation $EHC

Lecap Asset Management Ltd. purchased a new position in Encompass Health Corporation (NYSE:EHC) during the second quarter, HoldingsChannel reports. The firm purchased 6,054 shares of the company’s stock, valued at approximately $742,000.

A number of other hedge funds also recently bought and sold shares of EHC. Congress Asset Management Co. bought a new position in Encompass Health in the second quarter valued at about $92,691,000. Nuveen LLC bought a new position in shares of Encompass Health in the 1st quarter worth approximately $50,665,000. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Encompass Health by 25.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock worth $210,756,000 after buying an additional 424,691 shares during the last quarter. Strs Ohio bought a new stake in Encompass Health during the first quarter valued at approximately $34,364,000. Finally, American Century Companies Inc. increased its holdings in Encompass Health by 78.6% during the first quarter. American Century Companies Inc. now owns 723,169 shares of the company’s stock valued at $73,243,000 after buying an additional 318,251 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Down 0.8%

NYSE EHC opened at $123.58 on Friday. Encompass Health Corporation has a 12 month low of $87.85 and a 12 month high of $127.86. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The stock has a market cap of $12.45 billion, a PE ratio of 24.18, a P/E/G ratio of 2.18 and a beta of 0.93. The stock’s 50 day moving average is $120.94 and its 200 day moving average is $115.37.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.20. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period last year, the firm posted $1.11 EPS. The company’s revenue was up 12.0% on a year-over-year basis. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. Research analysts predict that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.6%. The ex-dividend date is Wednesday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.17. Encompass Health’s dividend payout ratio is presently 14.87%.

Insider Activity at Encompass Health

In other news, EVP Patrick William Tuer sold 1,020 shares of the firm’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

EHC has been the topic of a number of recent research reports. Stephens raised Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 target price on the stock in a report on Thursday, June 5th. Bank of America raised their price objective on Encompass Health from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, September 10th. UBS Group boosted their price objective on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial raised their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Finally, KeyCorp upped their price target on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $139.86.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.